Ultralife Reports Q4 GAAP Loss of $0.45/Share Driven by Impairment, Despite Revenue Growth
Summary
Ultralife Corporation reported fourth-quarter 2025 revenue of $48.5 million, a GAAP net loss of $0.45 per share, and adjusted EBITDA of $5.7 million. The net loss was primarily driven by a significant $12.2 million non-cash intangible asset impairment charge, which reduced EPS by $0.57. While an earlier Dow Jones report highlighted a Q4 net loss due to impairment, this release provides the full financial details. Despite the GAAP loss, revenue increased year-over-year, adjusted EBITDA remained positive, and backlog grew 22% quarter-over-quarter to $110.2 million, indicating some operational strength. Investors will be watching how the company's operational performance continues to evolve and the impact of its rebranding and consolidation efforts.
At the time of this announcement, ULBI was trading at $5.73 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $95.4M. The 52-week trading range was $4.07 to $9.52. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.